0.04
0.04 (-106.20%)
As of Jul 25, 2023
Humanigen, Inc [HGEN]
Source:
Company Overview
Humanigen, Inc is a clinical stage biopharmaceutical company, developing our portfolio of proprietary Humaneered anti-inflammatory immunologyand immuno-oncology monoclonal antibodies.
| Country | United States |
| Headquarters | short hills, new jersey |
| Phone Number | (973) 200-3100 |
| Industry | manufacturing |
| CEO | Cameron Durrant |
| Website | www.humanigen.com. |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.2 |
| Operating Profit | $-4.2 |
| Net Income | $-4.2 |
| Net Cash | $-7.1 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -1,916.3 |
| Profit as % of Revenues | |
| Profit as % of Assets | -51.3% |
| Profit as % of Stockholder Equity | 8.4% |
Management Effectiveness
| Return on Equity | 8.4% |
| Return on Assets | -81.7% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $5.1 |
| Total Liabilities | $54.8 |
| Operating Cash Flow | $-7.1 |
| Investing Cash Flow | |
| Financing Cash Flow |
